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ABSTRACT 
Purpose: Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer 
is driven by cells possessing stem-like properties of self-renewal and differentiation, 
referred to as Cancer Stem Cells (CSCs). CSCs are implicated in radiotherapy, 
chemotherapy resistance, and tumor recurrence. Notch promotes breast CSCs survival 
and self-renewal, and overexpression of Notch1 and the Notch ligand Jagged1 predict 
poor outcome. Resistance to anti-HER2 therapy in HER2+ breast cancer requires 
Notch1, and that combination of trastuzumab and a Gamma Secretase Inhibitor (GSI) 
prevents tumor relapse in xenograft models.  
Experimental Design: The current study investigates mechanisms by which HER2 
tyrosine kinase activity regulates Notch-dependent CSC survival and tumor initiation. 
Results: Lapatinib-mediated HER2 inhibition shifts the population of HER2+ breast 
cancer cells from low membrane Jagged1 expressing to higher levels, independent of 
sensitivity to anti-HER2 treatment within the bulk cell population. This increase in 
membrane Jagged1 is associated with higher Notch receptor expression, activation, 
and enrichment of CSCs in vitro and in vivo. Importantly, lapatinib treatment results in 
growth arrest and cell death of Jagged1 low-expressing cells while the Jagged1 high-
expressing cells continue to cycle. High membrane Jagged1 protein expression predicts 
poor overall cumulative survival in women with HER2+ breast cancer. Conclusions: 
These results indicate that higher membrane Jagged1 expression may be used to either 
predict response to anti-HER2 therapy or for detection of Notch sensitive CSCs post 
therapy. Sequential blockade of HER2 followed by Jagged1 or Notch could be more 
effective than simultaneous blockade to prevent drug resistance and tumor progression. 
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TRANSLATIONAL RELEVANCE 
Critical concerns for women with HER2+ breast cancer are drug resistance, tumor 
recurrence, and disease progression. The current study describes a novel role for 
membrane Jagged1 in enrichment of breast CSCs and resistance to anti-HER2 therapy. 
The clinical significance of this work is that higher membrane Jagged1 is a biomarker 
for higher Notch activation, and it predicts poor overall cumulative survival. Sequential 
blockade of HER2 followed by Jagged1 or Notch could be more effective than 
simultaneous blockade to prevent drug resistance and tumor progression.  
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INTRODUCTION: 
Breast cancer remains the most common form of cancer among women worldwide. By 
2026, it is estimated that there will be approximately 4,571,210 breast cancer survivors 
in the United States. Gene expression profiling has revealed distinct intrinsic subtypes 
of breast cancer. There are four major classes – Luminal A, Luminal B, human 
epidermal growth factor receptor 2 enriched (HER2+) and basal-like (1-3). 
Approximately, 15-20% of breast cancers are HER2+ (4, 5). These cancers contain 
amplification for a section of chromosome 17q containing the ERBB2 gene locus and 
neighboring genes GRB7 and MIEN1, accompanied by protein overexpression of HER2 
detectable as 3+ staining by immunohistochemistry (6). Treatment options include the 
use of biologics, trastuzumab and pertuzumab, along with taxane-based chemotherapy, 
use of the antibody drug conjugate TDM1 (trastuzumab emtansine) or dual epidermal 
growth factor receptor (EGFR)/ HER2 tyrosine kinase inhibitor lapatinib (6).  
Despite improved prognosis for women with HER2+ breast cancer, drug resistance, 
disease progression, and tumor recurrence remain major challenges preventing a cure 
(6). It is estimated that less than 35% of the patients initially respond to trastuzumab. 
This could be deemed as primary or intrinsic resistance (7, 8). Out of those who 
respond, about 70% exhibit metastatic progression within one year, suggesting 
secondary or acquired drug resistance (9). Drug resistance could be due to multiple 
factors including survival of resistant cells referred to as cancer stem cells (CSCs). The 
CSC hypothesis suggests that a tumor is comprised of a heterogeneous population of 
cells including small subsets or clones with stem-like properties. These stem-like 
properties can be intrinsic to cell clones or acquired through epigenetic remodeling by 
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hypoxia, EMT or treatment-induced cell stress. These small subsets of stem-like cells 
(CSCs) are thought to be selected by treatment which kills the majority of non-stem-like 
cells, while the surviving CSCs are responsible for drug-resistant recurrences (10). 
Notch signaling has been implicated in mammary stem cell self-renewal as well as in 
survival and self-renewal of breast CSCs (11, 12).  
Notch signaling is a developmentally conserved signaling pathway mediating 
communications between cells. Typically, the ligand is expressed on the signal sending 
cell and the receptor is expressed on the signal receiving cell. Mammals express five 
Notch ligands (Jagged1, Jagged-2, Delta-like 1, 3, and 4), and four Notch receptors 
(Notch1-4). Delta-like 3 is thought to be an inhibitory ligand, while Delta-like 1 and 4 and 
Jagged1 and 2 are stimulatory ligands. The relative affinity of Notch receptors for 
different ligand classes is modulated by glycosylation of the extracellular subunits of 
Notch receptors mediated by Fringe family N-acetyl-glucosaminidyltransferases, 
POFUT fucosyltransferase, and Rumi glucosyl transferase (13). When a ligand engages 
a receptor, it is ubiquitinylated by an E3 ligase, Neuralized or Mindbomb (14). This 
allows the ligand to be endocytosed into ligand expressing cells with the extracellular 
subunit of the Notch receptor, separating the latter from the transmembrane subunit. 
The receptor transmembrane subunit then undergoes subsequent cleavages by 
ADAM10 and finally by J-secretase, to release the Notch intracellular domain (NICD). 
NICD trans-locates into the nucleus of the signal receiving cell to initiate the 
transcription of Notch target genes (15). Overexpression of intracellular domains of 
Notch1, Notch3, and Notch4 in the mammary gland of mice leads to the formation of 
metastatic and aggressive breast tumors (16, 17). Notch1, Notch3, and Notch4 
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receptors are required for survival and self-renewal of breast CSCs (18-20). High co-
expression of Notch1 and Jagged1 transcripts are associated with poor overall survival 
of women with breast cancer (21). High levels of Jagged1 transcripts are associated 
with increased stem cell self-renewal in the Luminal subtypes of breast cancer (22). 
Further, increased Jagged1 expression has recently been implicated in promoting stem-
ness and angiogenesis (23). Recent reports showed that a Jagged1-Notch-4 axis is 
critical for mediating endocrine resistance and survival of breast CSCs (24). We have 
shown previously that Notch1 or Jagged1 is necessary for mediating trastuzumab 
resistance (25-27). Further, previous results demonstrated that Notch signaling is 
necessary for dormancy and tumor recurrence following anti-HER2 therapy (28, 29).   
Here, we show that overexpression and importantly, hyperactivity of HER2 restricts 
Jagged1 cell surface expression. When HER2 is inactivated by lapatinib, there is an 
increase in cell surface Jagged1, Notch target gene expression, % of cells in the S-
phase of the cell cycle, and increased survival of breast CSCs. In HER2+ breast cancer 
tissue, higher Jagged1 membrane staining, but not cytoplasmic or perinuclear Jagged1 
expression, predicts poor overall survival for women with primary, invasive HER2+ 
breast cancer. Overall, results of the study demonstrate that HER2 expression and 
activity status specifically restricts high membrane Jagged-1-enriched breast CSCs. The 
consequence of HER2 inactivation is a shift from low Jagged1 membrane expression to 
high Jagged-1 membrane expression responsible for breast CSCs that are resistant to 
lapatinib.  
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MATERIALS AND METHODS: 
Cell Culture 
HCC1954, MDA-MB-453 and MCF-7 cells were purchased from American Type Culture 
Collection (Manassas, VA). MCF-7 cells stably overexpressing HER2, designated as 
MCF-7-HER2, were generously provided by Dr. Mien-Chie Hung from The University of 
Texas, M.D. Anderson Cancer Center in Houston, Texas. HCC1954 and MDA-MB-453 
cells were grown in Dulbecco's Modified Eagle Medium (DMEM, Thermo Fischer 
Scientific, Waltham, MA), whereas MCF7 and MCF7-HER2 cells were cultured in 
Roswell Park Memorial Institute medium (RPMI-1640, Thermo Fischer Scientific, 
Waltham, MA). The cell culture media was supplemented with 10% fetal bovine serum 
(FBS, Gemini Bio-Products, Sacramento, CA), 1% L-glutamine (2 mM, Thermo Fischer 
Scientific, Waltham, MA) and 1% non-essential amino acids (100 µM, Invitrogen, 
Carlsbad, CA). Cell lines were authenticated using short tandem repeat allelic profiling 
(DCC Medical) in 2015 and maintained at low passage numbers (below 20). All cell 
lines were maintained by incubating at 37oC with 95% humidity and 5% CO2. 
 
Drugs and Chemicals: 
A J-secretase inhibitor (GSI), MRK-003 was provided by Merck Oncology & Co. 
(Whitehouse Station, NJ). For in vitro studies, 5 mM MRK-003 GSI stock solution was 
prepared by dissolving in dimethyl sulfoxide (DMSO). The working concentration was 5 
µM and the prepared drug was stored at -80oC for future use. Lapatinib, a dual HER2-
EGFR tyrosine kinase inhibitor was purchased from Selleck Chemicals, Houston, TX. 
For in vitro studies, 4 mM stock concentration of lapatinib was prepared by dissolving it 
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in dimethyl sulfoxide (DMSO). The working concentration was 2 µM and the prepared 
drug was stored at -80oC for future use. 
 
RNA Interference and Transfection Reagents: 
Jagged1 stealth small interfering RNA (siRNA) having two different sequences was 
purchased from Thermo Fisher Scientific, Waltham, MA (Cat. HSS176254 and 
HSS176255). The sequences were Jagged1 A (GATAACTGTGCGAACATCACATTTA) 
and Jagged1 B (CGCGACGAGTGTGACACATACTTCA). HER2 siRNA 
(rGrCrCrArArCrArArArGrArArArUrCrUrUrArGrArCrGrAAG) was purchased from 
Origene, Rockville, MD (Cat. SR301443). Non-targeting scrambled control siRNA was 
purchased from Qiagen, Germantown, MD (Cat. 1027281). The transfection reagents 
Lipofectamine 3000 (Cat. L3000015) and Lipofectamine RNAiMax (Cat. 13778150) 
were purchased from Thermo-Fisher Scientific, Waltham, MA. Lipofectamine 3000 was 
used for Jagged1 knockdown and Lipofectamine RNAimax was used to knockdown 
HER2. The siRNAs were reconstituted with RNAse free water to yield a stock 
concentration of 10 µM. The final working concentration of the siRNA was 10 nM. For 
Jagged1 siRNA transfection, 17 µL siRNA and 17 µL of lipofectamine 300 or equal 
volume of siRNA to RNAiMax was used in a 60mm plate. For HER2 siRNA transfection, 
20 µL of siRNA and 20 µL RNAimax was used in a 60mm plate. The transfection was 
performed according to the manufacturer’s protocol.  
 
Flow Cytometry: 
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HCC1954 (250,000 cells/well – 6 well plate), MDA-MB-453 (350,000 cells/well – 6 well 
plate for treatment and 700,000 cells/well – 60 mm plate for transfection), MCF-7 
(40,000 cells/well – 6 well plate), or MCF-7-HER2 (40,000 cells/well – 6 well plate) were 
treated for four days with DMSO or 2µM lapatinib (Cat. S1028, Selleck). For 4 days of 
lapatinib treatment, cells were trypsinized and replated after 2 days at a similar density. 
This was done to avoid over-confluency and to maintain similar density. The impact of 
pharmacologic inhibition of HER2 on the surface expression of Jagged1 was assessed 
using flow cytometry. The cultured cells were harvested using gentle trypsinization or 
Cellstripper (Cat.25–056-CI, Corning Cellgro, Manassas, VA). The harvested cells were 
neutralized using DMEM media and the cell suspension was centrifuged at 1300 rpm for 
3 minutes. Followed by this, the cell pellet was resuspended in 2 ml flow cytometry 
staining buffer (Cat. FC001, R&D Systems, Minneapolis, MN) and the cell suspension 
was transferred into FACS tube. The cells were then washed twice with 2 ml flow 
cytometry staining buffer by centrifuging the cell suspension at 1300 rpm for 3 minutes 
in the presence of 100Pg/mL DNAse I to limit cell clumping. After the second wash, the 
excess staining buffer was aspirated, leaving about 250 µl of buffer and the cell pellet. 
The cells were then stained by using biotinylated human Jagged1 primary antibody 
(Cat. BAF1277, R&D Systems, Minneapolis, MN). About 3-6 µl of primary antibody was 
added to each tube containing 1– 2 million cells. The cell suspension/antibody mixture 
was then incubated for 45 minutes at room temperature. Subsequently, the cells were 
washed twice in flow cytometry staining buffer by centrifuging them at 1300 rpm for 3 
minutes. After the second wash, excess staining buffer was aspirated, leaving behind 
around 250 µl. To this cell suspension, APC conjugated secondary antibody (Cat. 
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405207, BioLegend, San Diego, CA) was added. All the subsequent steps were 
performed in the dark. The secondary antibody was diluted 20-fold using flow cytometry 
staining buffer and then 2-8 µl of the antibody was added to each tube containing 
100,000 – 1 million cells. The tubes were then incubated at room temperature for 45 
minutes. After the incubation, tubes were washed twice with flow cytometry staining 
buffer as described before. The cell pellet was finally resuspended in 250 µl flow 
cytometry staining buffer for analysis by using BD FACS Canto II (BD BioSciences, San 
Jose, CA). Data was captured using BD FACSDiva software. Data analysis was 
performed using FlowJo software. Specificity of Jagged1 expression by flow cytometry 
was confirmed using a Jagged1 siRNA. For CD44 High/CD24 low assay, HCC1954 
cells were harvested and stained per the protocol described above. The cells were 
stained with APC conjugated CD44 (Cat. 103012, BioLegend, San Diego, CA)/ FITC 
conjugated CD44 (Cat. 103021 BioLegend, San Diego, CA) and PE conjugated CD24 
(Cat. 311106, BioLegend, San Diego, CA), and were analyzed as mentioned above.  
 
Cell Sorting: 
HCC1954 or MCF-7-HER2 cells were treated with DMSO or 2 µM lapatinib for 4 days, 
and were stained with biotinylated Jagged1 (3-8 µL/1-2 million cells) and streptavidin-
APC antibodies (5 µL undiluted) as described previously. To sort sufficient cells 
(HCC1954 and MCF-7-HER2), 2 T150 flasks (4 million cells/flask) were used for DMSO 
treatment and 3 T150 flasks (4.5 million cells/flask) were used for lapatinib treatment. 
After staining, cells were sorted based on Jagged1 surface expression (Jagged Low 
and Jagged High) by a BD FACSAria cell sorter (BD BioSciences, San Jose, CA). The 
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cells were sorted into 24 well plates containing mammosphere medium (35,000 
cells/well) supplemented with DMSO/5 µM GSI for mammosphere assays. The cells 
were sorted into FACS tubes to perform Aldefluor assays, CD44 high/CD24 low 
assessment, and to detect the expression of Notch target genes. Subsequently, cell 
suspensions were centrifuged at 1300 rpm for 3 minutes, and cells were then used for 
performing these assays. The detailed protocols for mammopshere assays, Aldefluor 
assays, CD44 high/CD24 low assessment and detection of Notch target genes using 
real-time PCR are described below. Control experiments were performed whereby 
HCC1954 cells (3-T150 flasks) were stained for Jagged1 surface expression as 
described above, and Jagged1-high and Jagged1-low cells were sorted (25,000 
cells/well) into 24 well plates containing mammosphere media supplemented with 
DMSO/ 5 µM GSI. Mammosphere formation was assessed as described previously 
(30).  
 
Cell Proliferation Assays: 
Cells HCC1954, MCF-7, or MCF-7-HER2) were plated at a known density as described 
previously and then subsequently treated every day with vehicle (DMSO) or 2PM 
lapatinib up to 4 days. Total numbers of viable cells were counted using the Countess 
Cell Counter. Cell cycle analysis was conducted using propidium iodide according to the 
manufacturer’s instructions (Cell Signaling Technology).  
 
Aldefluor Assay: 
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Aldehyde Dehydrogenase ALDH1A1 is one of the 19 ALDH isoforms expressed in 
humans, and is believed to be responsible for the ALDH activity of CSCs. ALDH is a 
detoxifying enzyme, and is responsible for the oxidation of intracellular aldehydes. An 
Aldefluor kit (Cat. 01700, STEMCELL Technologies, Vancouver, Canada) was used to 
detect the cancer stem cell (CSC) population based on the enzymatic activity of 
aldehyde dehydrogenase 1 (ALDH1A1). Two tubes containing 200k sorted/ unsorted 
HCC1954 cells suspended into 1mL of Aldefluor assay buffer were prepared – a test 
tube that received 5 µl ALDH1A1 substrate, and a control tube that received 10 PL 
aldehyde dehydrogenase inhibitor N, N-diethylaminobenzaldehyde (DEAB) and 5 µl 
substrate. The tubes were incubated at 37oC for 45 minutes in the dark, put on ice and 
centrifuged for 5 mins at 250g. The supernatant was then removed and the cell pellet 
was resuspended into 0.5 mL Aldefluor assay buffer. The tubes were then put on ice 
and were analyzed using flow cytometry as mentioned before. Live cells were gated 
based on propidium iodide staining and forward and side scatter. Percent Aldefluor 
positive cells were determined in the DEAB negative sample compared to the DEAB 
positive sample based on ALDH- cell gating assignments. Three gating assignments 
were assessed: ALDH-high, moderate, and low. 
 
Mammosphere Forming Assay: 
This protocol is a modified version of the Shaw et al assay (30). Preparation of Methyl 
Cellulose based Mammosphere Medium – 196 mL of DMEM-F12 medium (Cat. 
11039021, Gibco) was warmed at 60oC and added to a bottle containing 2g of methyl 
cellulose. The contents were then allowed to stir at 60oC for 2.5 hr until methyl cellulose 
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was uniformly mixed. The DMEM-F12 methyl cellulose medium-mixture was then stirred 
overnight at 4oC. The following day, 4 mL B-27 supplement and 4 µL recombinant hEGF 
(Cat. E-9644, Sigma Aldrich) was added to the medium. The medium was then stirred 
at 4oC for 30 mins and then transferred into centrifuge tubes. The tubes were then 
centrifuged at 9500 rpm in a Beckman rotor at 4oC for 30 mins. The supernatant 
(mammosphere medium) was poured into 50 mL conical tubes after centrifugation. The 
tube containing-mammosphere medium was incubated in a bead bath at 37oC for 2-3 
hours prior to use. Excess mammosphere medium was stored at -20oC for future use. 
To perform a mammosphere forming assay, cells were harvested using trypsin or 
FACs-sorted. The single cell suspension was prepared and 100,000 cells/well (6 well 
ultra-low attachment plates) or 35,000 cells/well (24 well ultra-low attachment plates) 
were added into the mammosphere medium containing vehicle control DMSO or 5 µM 
MRK-003 GSI.  
In order to study the effect of Jagged1 knockdown, 600,000 HCC1954 or MCF-7-HER2 
cells were plated into 60mm plates. 3 plates each were used for transfection of non-
targeting siRNA or Jagged1 siRNA. The transfection was performed as described 
previously. After transfection, cells were harvested and re-plated for DMSO or lapatinib 
treatment for 4 days. After treatment, 100,000 cells in a single cell suspension were 
used for mammosphere forming assays, and the remaining cells were used for Western 
blots. After the addition or sorting of the cells, mammosphere plates were rocked back 
and forth several times to ensure that the cell suspension was evenly distributed. The 
mammosphere plates were then incubated at 37oC and 5% CO2 for 7-10 days, after 
which mammospheres were harvested and counted. In order to harvest the 
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mammospheres, 2 mL PBS was added to the well containing mammospheres. The 
mixture of PBS and mammopshres was pipetted gently a few times and was transferred 
into 15 mL conical tube. This process was repeated 3-4 times. The plate was observed 
under the microscope to ensure that all the mammopsheres were harvested. 15 mL 
conical tubes containing mammosphere suspensions were centrifuged at 1500 rpm for 
5 minutes. The supernatant was aspirated and 2 mL PBS was added to the 
mammosphere pellet. The mix was then transferred to a 2mL tube and was centrifuged 
at 5000 rpm for 5 mins. One more wash with 2 ml PBS was performed and then the 
mammosphere pellet was again re-suspended into 2mL PBS (2 ml PBS was used as 
resuspension volume if 100k cells were plated. For 35,000 sorted cells, 500 µL PBS 
was used for resuspension). After resuspension, 50 µL was transferred into a well of a 
96 well plate. 350 µL PBS was then added to the well. Mammosphere-containing wells 
were photographed under a microscope and five fields were taken at 4X magnification. 
The photographs contained a measurement scale. Taking five fields ensured that the 
photographs captured all the mammospheres in the well. The photographs were then 
transferred into PowerPoint and the mammospheres were manually counted, based on 
the scale present in the picture. The size cut-off was 50 µm i.e. all the spheres ≥ 50 µm 
were counted as mammospheres. Based on resuspension volume, the dilution factor 
was used to count the total mammospheres. Percentage mammosphere forming 
efficiency was defined as 100*(Number of mammospheres/ number of cells plated). 
 
Tumor Initiating Potential: 
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HCC1954 cells were treated with either DMSO or 2 µM lapatinib for 4 days and were 
sorted by flow cytometry on the basis of Jagged1 surface expression. For pilot 
experiments, 10,000 sorted cells were injected into mammary fat pads of 5 female, 
ovariectomized FoxN1 nu/nu athymic nude mice (Harlan Sprague-Dawley, Madison, 
WI). During the course of the study, each mouse and its tumor was tracked using an ear 
tag. Tumor take was assessed for up to 8 weeks and the tumorigenic potential of the 
two subpopulations was calculated. In order to perform a limiting dilution assay to detect 
the frequency of CSC formation, mice were randomized into following groups – 100/ 
1000/ 10,000 DMSO Jagged Low cells/site (n=8-10 per group) or 100/ 1000/ 10,000 
Lapatinib Jagged High cells/site (n=8-10 per group). Beginning one week after injection, 
tumor formation was assessed weekly. Tumors were measured by using Vernier 
calipers and the tumor area (l x w) was calculated and graphed. At the end of seven 
weeks, the number of mice that developed a tumor ≥ 40 mm2 was determined and the 
tumor initiating potential was calculated by using the Extreme Limiting Dilution Analysis 
(ELDA) software. The protocol for animal study was approved by Loyola University’s 
Institutional Animal Care and Use Committee (IACUC).  
 
Immunohistochemical staining of human HER2+ breast tumors: 
The Nottingham Tenovus Primary Breast Carcinoma Series were used. These are a 
series of 1,944 cases of primary operable invasive breast carcinoma from woman 
diagnosed from 1986–1998 (31). Primary, invasive stage II-III HER2+ breast tumor 
tissues were adhered by placing the tissue microarray (TMA) sections in an oven at 
58oC to 60oC.  Xylene was used for de-paraffinizing the tissue followed by rehydration 
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using ethanol, and washed with PBS 1X Reveal treatment in a Decloaking Chamber 
(Biocare Medical) for antigen retrieval. Once the TMA sections were rinsed by PBS for 
15 minutes, sections were treated using 3%H2O2 in PBS for 20 minutes to quench 
endogenous peroxidase activity. Sections were incubated for one hour in 3% normal 
rabbit serum (Vector Laboratories) in PBS at room temperature to block non-specific 
binding. Sections were then incubated with primary antibody (anti-Jagged1) prepared in 
PBS containing 1.5% normal rabbit serum and were incubated for one hour in a 
hydrated chamber at room temperature. TMA sections incubated with 1μg/ml normal 
goat IgG (Santa Cruz Biotechnologies, CA) were used as negative controls. Following 
multiple washing, antigen-antibody complexes were detected using the Vectastain Elite 
ABC kit (Vector Laboratories, CA) as per the manufacturer’s protocol. Staining was 
performed with ImmPactTM DAB peroxidase substrate kit (Vector Laboratories, CA). 
Sections were then counterstained in Gill’s hematoxylin and dehydrated in ascending 
grades of ethanol before clearing in xylene and mounting under a coverslip using 
Cytoseal XYL. The levels of Jagged1 protein expression in each specimen were scored 
per the extent (percent of stained cells) and intensity of staining. The score for the 
extent of the IHC stained area was scaled as 0 for no IHC signal at all and 1 for 10–80 
tumor cells stained. Stained slides were sent to Nottingham, England where they were 
scanned. High-resolution images were uploaded to the Nottingham web-accessible 
scoring site, and were scored by 2 independent investigators (Drs. Alexandra Filopovic 
and Lucio Miele). Intensity scores (0-1), percent staining scores and H-Scores were 
uploaded as Excel spreadsheets and survival analysis was performed using SPSS. All 
patients enrolled in this study provided a written consent. This study was approved by 
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the Nottingham Research Ethics Committee 2 under the title ‘Development of a 
molecular genetic classification of breast cancer' and the study was carried out 
according to recognized United Kingdom ethical guidelines. 
 
Western Blot Analysis:  
HCC1954, MCF-7, and MCF-7-HER2 cells were transfected with siRNA and/or treated 
with DMSO or 2 μM lapatinib for 4 days. The cells were maintained in the incubator at 
370C with 95% air and 5% CO2. After transfection and/or treatment, the medium was 
aspirated and cells were washed twice using ice-cold phosphate-buffered saline (PBS). 
Depending upon the cell confluency and the size of the plate, 150 μL-300 μL of Triton 
X-100 lysis buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
1% Triton X-100,150 mM sodium chloride (NaCl), 5 mM ethylene-diaminetetraacetic 
acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium orthovanadate, 
10 mM sodium fluoride (NaF), 1 protease inhibitor cocktail tablet) was used to lyse the 
cells. The cells were then scraped using a cell scraper, and the lysate was collected into 
Eppendorf tubes. The lysate was allowed to incubate on ice for 10 minutes. The cells 
were sonicated 3 times for 10 seconds each using the Sonic Dismembrator (Model 100, 
Thermo-Fischer Scientific, Waltham, MA). Protein concentration was determined using 
Pierce bicinchoninic acid (BCA) Protein Assay kit (Thermo Fisher Scientific, Waltham, 
MA, Cat. 23225). Based on the protein concentration, protein samples were prepared 
(20 μg – 50 μg) using 2X or 4X Laemmli buffer (BioRad, Hercules, CA, Cat. 1610737 or 
1610747) and beta-mercaptoethanol (Thermo Fischer Scientific, Waltham, MA, Cat. BP-
176-100). The samples were boiled at 950C for 5 minutes. The denatured protein 
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samples were then run on 7% tris-acetate PAGE gels (Thermo Fisher Scientific, 
Waltham, MA, Cat. EA0358BOX) along with HiMark Prestained protein standard 
(Thermo Fisher Scientific, Waltham, MA, Cat. LC5699) at 150V for 60 minutes. 20X 
NuPAGE Tris-Acetate SDS Running Buffer (Thermo Fisher Scientific, Waltham, MA, 
Cat. LA0041) was diluted using deionized water. Separated proteins were then 
transferred onto Polyvinylidene difluoride (PVDF) membrane. After transfer, the 
membrane was rewetted in methanol and water and was blocked using 5% non-fat dry 
milk, 20% Roche buffer or 5% BSA (used for phosphorylated proteins) for 1 hour at 
room temperature. TBST (5 mM Tris-HCl, 5 mM Tris-base, 150 mM NaCl, 0.05% 
Tween-20, and 0.2% NP-40 at pH 8.0) was used for the dilution of non-fat dry milk or 
BSA, whereas Tris-buffered saline (TBS) was used for the dilution of Roche buffer. After 
blocking, the membrane was incubated overnight with primary antibody at 40C with 
constant shaking. The primary antibody was diluted at the recommended concentration 
in the diluent that was used for blocking. The following day, the membrane was washed 
3 times using TBST. Each wash was for 10 minutes and the blots were shaken 
vigorously at room temperature. After the washes, the secondary antibody was added 
and the membrane was incubated at room temperature for 1 hour, with constant 
rocking. The dilution buffer for the secondary antibody was the same as the one used 
for primary antibody. Followed by this, the membrane was again washed for three times 
using TBST. After the final wash, proteins were detected using enhanced 
chemiluminescence (ECL) Western blotting substrate (Pierce, Rockford, IL) or 
SuperSignal® West Dura (Thermo Fischer Scientific, Waltham, MA) added in 1:1 
volume. The membrane was incubated for 1 minute at room temperature. Protein bands 
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were visualized by exposing the membrane to X-ray film in the dark room. To reprobe 
membranes, they were washed in TBST at room temperature for 10 minutes and then 
stripped using Restore Plus Western Blot Stripping buffer (Thermo Fischer Scientific, 
Waltham, MA). The membrane was covered with stripping buffer and incubated for 20 
minutes at 370C. The membrane was washed three times using TBST as mentioned 
before, blocked and probed with the primary antibody of interest. 
 
Real-time PCR: 
HCC1954 cells were treated for four days with DMSO or 2 µM lapatinib. Cells were 
sorted by flow cytometry on the basis of Jagged1 surface expression as described 
previously. For unsorted cells, total RNA was extracted according to the manufacturer’s 
protocol using RiboPure RNA Purification kit (Ambion, Austin, TX, Cat. AM1924). For 
cells sorted on the basis of Jagged1 surface expression, RNeasy Plus Micro Kit 
(Qiagen, Germantown, MD, Cat. 74034) was used for RNA extraction, as this kit is more 
suitable for small numbers of cells. After extraction, the RNA yield was determined by 
using the NanoDrop Spectrophotometer (Thermo Fischer Scientific, Waltham, MA). The 
cDNA was synthesized through reverse transcription by using 1 µg RNA in 100 µL 
volume containing 1X RT buffer, 5.5 mM MgCl2, 500 µM dNTPs, 2.5 µM random 
hexamers, 0.4 U/µl RNase inhibitors, and 1.25 U/µl RT enzyme (MultiScribe™ Reverse 
Transcriptase Kit, Applied Biosystems, Foster City, CA, Cat. N8080234). For reverse 
transcription, parameters were as follows: 10 minutes at 250C, 30 minutes at 480C, 5 
minutes at 950C, 60 minutes at 250C, and at 40C until use. After the cDNA was 
synthesized, real-time PCR was performed using iTaq™ SYBR® Green Supermix with 
21 
 
ROX (BioRad, Hercules, CA) to detect the transcript levels of Notch receptors and 
Notch target genes. In a 96 well plate, 2.5 µL of prepared cDNA was added to 22.5 µL 
of a mastermix-containing 2X SYBR Green Universal Master Mix, and 50 µM forward 
and reverse primers for the intended target. The assay was performed in triplicate wells 
of 96-well plate. The plate was then sealed to prevent evaporation and quantitative Real 
Time PCR was performed using following parameters: the initial denaturation was for 10 
minutes at 950C; PCR cycling for 40 cycles was carried out for 10 seconds at 950C and 
45 seconds at 600C. A melt curve was added after completion of the 40 cycles set by 
the StepOnePlus thermocycler manufacturer (Applied Biosystems, Foster City, CA). 
Relative expression of various gene transcripts in different samples was calculated 
based on the Ct value. Ct value indicates the number of cycles that were required to 
detect the initiation of amplification of the cDNA amplicon. Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) gene transcripts were used as an endogenous 
control for normalizing the Ct values. Relative fold change in the gene expression 
between different samples was calculated on the basis of 2 (-ΔΔ Ct)  method – ΔCt sample 
= [Ct value of gene of interest (sample) - Ct value of HPRT(sample)] ΔCt control = [Ct 
value of gene of interest (control) - Ct value of HPRT(control)] ΔΔCt = (ΔCt sample - ΔCt 
control) Fold change in gene expression = 2 (-ΔΔCt)  The primer sequences that were 
used for detecting the gene transcript expression are listed in Supplemental Table 1. 
 
Statistical Analysis: 
The experiments were performed at least three independent times and results were 
reported as Mean ± standard deviation (S.D.). For data involving two comparisons, 
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Microsoft Excel was used to perform an unpaired, two-tailed Student’s T-test. Multiple 
comparisons were done using ANOVA (Tukey’s test for multiple comparison) and 
GraphPad Prism 6 was used for the analysis. All the graphs were generated using 
GraphPad Prism 6. Extreme Limiting Dilution Analysis (ELDA) software 
(http://bioinf.wehi.edu.au/software/elda/) was used to calculate CSC frequency for the 
limiting dilution in vivo study.  Kaplan-Meier curves were generated for the overall 
survival of women with HER2+ breast cancer, and for % tumor free mice. Statistical 
significance was calculated using the Log rank, Mantel-Cox test.  
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RESULTS: 
Pharmacologic inhibition of HER2 increases survival of CSCs 
Since Notch activation was required for HER2+ tumor recurrence post-anti-HER2 
therapy (28, 29), we tested if Notch activation is necessary for the formation of CSCs 
derived from HER2+ breast cancer cells in response to anti-HER2 therapy. Lapatinib 
was chosen as a pharmacologic inhibitor of HER2 signaling due to its high efficacy in 
cell culture models and its use as second/third line therapy in trastuzumab-refractory 
disease (32). Results showed that lapatinib increased mammopshere forming efficiency 
(MFE), a surrogate assay for CSC survival (30), in HER2+ breast cancer cells, 
HCC1954 (Figure 1A) and MCF-7-HER2 cells (Figure 1B), whereas it did not 
significantly affect mammosphere formation in HER2 non-overexpressing MCF-7 cells 
(Figure 1C). Furthermore, the MRK-003 GSI inhibited mammosphere formation in these 
cell lines (Figure 1A-C), confirming previous reports that Notch activation is required for 
breast cancer stem survival (11, 18, 20, 33). To test whether the increase in %MFE in 
response to lapatinib was due to growth inhibition of bulk cells, bulk cell proliferation 
assays were conducted. Proliferation of bulk HER2+ HCC1954 cells is inhibited by 
lapatinib, GSI or the combination (Suppl Figure 1A). In contrast, MCF-7-HER2 (Suppl 
Figure 1B) or MCF-7 (Suppl Figure 2C) cells are resistant to lapatinib with moderate 
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sensitivity to GSI. These results suggest that the lapatinib-mediated increase in CSCs is 
most likely independent of sensitivity of bulk cells to lapatinib or GSI.  
As lapatinib is a dual EGFR and HER2 tyrosine kinase inhibitor, expression levels of 
phosphorylated HER2 and EGFR in response to lapatinib were measured. HER2+ cells 
(HCC1954 and MCF-7-HER2) and HER2- wild type cells (MCF-7) express detectable 
levels of EGFR (Figure 1A-C, lower panels). Lapatinib treatment inhibited tyrosine 
phosphorylation of both EGFR and HER2 in HER2+ cells (Figure 1A and B, lower 
panels) but only inhibited EGFR in HER2- wild type MCF-7 cells (Figure 1C, lower 
panel).  These results suggest that the lapatinib-mediated increase in CSC survival from 
HER2+ breast cancer cells is most likely dependent on HER2 expression, not EGFR, 
and potentially independent of bulk cell sensitivity to lapatinib.  
 
Lapatinib Promotes Jagged1 Surface Expression 
Previous reports demonstrated that Jagged1 expression at both RNA and protein levels 
predict poor outcome and higher metastatic potential in women with breast cancer (21, 
34, 35). We previously published that HER2+ breast cancer cells express Jagged1 
protein but it is limited to intracellular compartments. Upon HER2 blockade using 
genetic or pharmacologic methods, Jagged1 localizes to the cell membrane and is 
required for Notch activation and resistance to anti-HER2 therapy (26).  Based on these 
previous findings, we investigated whether lapatinib enriched for Jagged1-high 
membrane expressing cells with CSC-like features and whether these cells were 
resistant to lapatinib.  Results showed that lapatinib treatment increased cell surface 
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Jagged1 expression as assessed by flow cytometry in HER2+ breast cancer cells, 
HCC1954 (Figure 2A), MCF-7-HER2 (Figure 2B), and MDA-MB-453 (Figure 2C), but 
not in MCF-7 cells that do not overexpress HER2 (Figure 2D). Control studies were 
conducted to assess specificity of the flow cytometry Jagged1 antibody. Controls 
showed that lapatinib treatment had little effect on the APC fluorophore channel in 
unstained cells (Suppl Figure 2A). Unstained cells were used as controls for all of the 
studies as they were identical to cells stained with the secondary antibody-conjugated to 
APC (Suppl Figure 2B). The lapatinib-induced increase in Jagged-1 cell surface staining 
was specific as RNAi-mediated knockdown of Jagged-1 almost completely prevented 
the increase (Suppl Figure 2C-E).  
Interestingly, Jagged1 transcripts were increased in response to lapatinib (Suppl Figure 
3A), but this did not correlate with total protein expression (Suppl Figure 3B), suggesting 
that while HER2 tyrosine kinase activity inhibits Jagged1 RNA expression, protein 
expression on the cell surface is regulated at a post-translational level.  
 
Lapatinib-mediated Jagged1-high expressing cells are enriched for CSCs and 
resistant to lapatinib  
Since HER2 inhibition in response to lapatinib resulted in an increase in MFE and an 
increase in Jagged1 surface expression, we tested whether lapatinib-induced Jagged1-
high-expressing cells have CSC-like features. HCC1954 cells were treated with vehicle 
(DMSO) or 2μM lapatinib for 4 days. The live cell populations based on propidium iodide 
exclusion were sorted based on gating for Jagged1-low (APC-low) and Jagged-1-high 
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(APC-high) after vehicle and lapatinib treatments and MFE was assessed (Figure 2E). 
The initial study showed that vehicle-treated Jagged-1 negative/low and the Jagged-1 
moderately higher sorted cells had little detectable MFE. Cells sorted after lapatinib 
treatment based on low versus high Jagged-1 staining had strikingly different 
phenotypes. The lapatinib Jagged-1-low sorted cells had little detectable MFE while the 
Jagged-1-high cells were the only cells with MFE (Figure 2E). Similar results were 
observed using the MCF-7-HER2 breast cancer cells (Suppl Figure 4).  
To assess the proliferative capacity of sorted cells based on Jagged1 surface 
expression, cell cycle analysis was performed after sorting. DMSO-treated HCC1954 
Jagged1-low expressing cells had lower % of cells in the S-phase (20%) compared to 
Jagged-1-high expressing cells (35%) (Suppl Figure 5). Upon lapatinib treatment, the 
majority of Jagged-1-low expressing cells were arrested in the G1-phase with 10% 
undergoing cell death. In contrast, nearly 20% of the lapatinib-induced Jagged-1-high 
expressing cells were in the S-phase (Suppl Figure 5). These results suggest that 
Jagged-1-low expressing cells are sensitive to lapatinib while the Jagged1-high 
expressing cells are resistant.   
Based on initial results, subsequent studies focused on sorted cells that expressed the 
lowest levels of Jagged-1 (vehicle treated) and the highest levels of Jagged-1 (lapatinib 
treated) on the cell surface. The vehicle-treated Jagged1-low population and lapatinib-
treated Jagged1-high population of HCC1954 or MCF-7-HER2 cells were sorted and 
assessed for CSC survival using MFE. The lapatinib-induced Jagged1-high population 
showed significantly higher MFE than the vehicle-treated, Jagged1-low population 
(Figure 3A). Inhibition of the J-secretase complex using the MRK-003 GSI completely 
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prevented mammosphere formation, suggesting that the enrichment of Jagged1-high 
breast CSCs by lapatinib was dependent on Notch activation (Figure 3A). Similar MFE 
results were observed for MCF-7-HER2 cells sorted based on vehicle treated Jagged-1-
low cells compared to lapatinib treated Jagged-1-high cells (Figure 3B).  
 
Lapatinib inhibits proliferation of bulk HCC1954 cells as assessed by fold decrease of 
viable cell numbers compared to DMSO after 4 days of treatment (Suppl Figure 1A). In 
contrast, lapatinib treatment increases Jagged-1 expression on the cell surface and 
these high Jagged-1 expressing cells have higher CSC survival and appear to be 
resistant to lapatinib.  
 
Lapatinib-induced Jagged1-high cells express higher Notch receptors and gene 
targets 
Since HER2 inhibition resulted in an increase in cell surface Jagged1 expression, we 
tested the status of Notch expression and activation in the subset of cells that 
expressed low compared to high Jagged1. HCC1954 cells were treated with lapatinib 
and then sorted based on Jagged1 cell surface expression. Notch receptors and Notch 
target gene transcripts were measured using real-time PCR. The lapatinib-treated 
Jagged1-high cells showed a significant increase in transcript levels of Notch1 and 
Notch3 compared to vehicle-treated Jagged1-low expressing cells (Figure 4A). Notch 
gene targets (HEY2, HES4, CCND1, and C-MYC) were also significantly increased in 
the Jagged-1-high expressing cells (Figure 4B). Notch signaling functions in a cell-cell 
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contact dependent manner. Surprisingly, the ligand expressing cells showed higher 
Notch activity. Notch receptors are typically activated in trans by ligands on a signal 
sending cell. However, if the Notch receptor and the Notch ligand are present on the 
same cell, this can lead to inhibition of Notch signaling, known as cis inhibition (36). To 
address this possibility, we performed flow cytometry to detect the surface co-
expression of Notch receptors and Jagged1. Results showed that approximately 50-
80% of vehicle treated HCC1954 cells express Notch1, Notch3, and Notch4 proteins on 
the cell surface with only 5-17% of cells co-expressing a Notch receptor and Jagged1 
(Figure 4C). Upon lapatinib treatment, the entire cell population shifts to higher 
expression of Jagged-1 while Notch receptor expression is maintained or decreased 
(Figure 4C). This suggests that HER2 inhibition enriches for Jagged1-
Notch1/Notch3/Notch4 high co-expressing cells allowing for ligand-receptor 
engagement to activate Notch signaling and increase survival of CSCs.  
 
Lapatinib-induced Jagged1-high expressing cells have higher Aldefluor activity. 
Expression of Aldehyde dehydrogenase1 (ALDH1A1) (37) and CD44/CD24 (38) levels 
have been reported to be markers of CSCs.  Recently, ALDH1A1 activity has been 
shown to be high in epithelial/luminal CSCs, while CD44-high/CD24-low expressing 
cells have been shown to be associated with mesenchymal/basal CSCs (39). The 
lapatinib-induced Jagged1-high-expressing sorted cells had significantly higher 
Aldefluor activity as compared to control Jagged1-low sorted cells (Suppl Figure 6). 
Aldefluor+ cell populations were assessed based on three distinct gatings: the entire 
Aldefluor+ population (Suppl Figure 6A), moderate (Suppl Figure 6B), and high (Suppl 
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Figure 6C). This result suggests that upon HER2 inhibition, higher Jagged1 expression 
on the cell surface is necessary for the enrichment of Aldefluor+ CSCs.  
HCC1954 cells contain a very small fraction of CD44-high/CD24-low cells (Suppl Figure 
7A). Lapatinib treatment divided the entire population into two subsets: CD44-
high/CD24-high and CD44-low/CD24-high. When cells were sorted based on Jagged-1 
surface expression, the vehicle Jagged-1-low expressing cells expressed similar levels 
of CD44/CD24 (i.e. CD44-high/CD24-moderate) compared to unsorted cells (Suppl 
Figure 7B). The lapatinib-induced Jagged-1-high expressing population were similar to 
unsorted cells (i.e. CD44-High/CD24-High and CD44-low/CD24-High) (Suppl Figure 
7B). MDA-MB-231 and MDA-MB-468 cells were used as positive and negative controls 
for CD44-high/CD24-low expressing cells, respectively (Suppl Figure 7C). These results 
suggest that HER2 inhibition selects for an epithelial/luminal population of CSCs that 
have high Jagged1 on the surface.  
 
Jagged1 is required for Lapatinib-mediated enrichment of CSCs in vitro 
Lapatinib-mediated HER2 inhibition resulted in an increase in MFE. Specifically, the 
lapatinib-induced Jagged1-high-expressing cells have increased MFE. To test whether 
the lapatinib-induced MFE was dependent on Jagged1, Jagged-1 was knockdown using 
two distinct siRNAs and MFE assessed. Jagged1 knockdown significantly reduced 
lapatinib-induced MFE (Figure 5A). Both siRNAs were efficient at reducing Jagged1 
protein levels (Figure 5B). These results indicate that Jagged1 is required for the 
increase in CSC survival in response to lapatinib.  
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The Lapatinib-induced Jagged1-high-expressing cells have high tumor initiating 
potential 
The in vitro results suggest that the Jagged1-high population in response to lapatinib 
treatment is enriched for CSCs and that Jagged1 is necessary for the formation of these 
CSCs. To assess the tumor initiating potential of the Jagged1-high population, a limiting 
dilution tumorigenesis experiment was performed in vivo. HCC1954 cells were sorted 
based on cell surface expression of Jagged1 by flow cytometry. Following the sort, 
10,000 vehicle-treated Jagged1-low cells or lapatinib-treated Jagged1-high cells were 
injected into the mammary fat pad of female, athymic nude mice and tumor incidence 
was assessed for 8 weeks. One hundred percent of the mice injected with the lapatinib-
treated Jagged1-high-expressing cells developed tumors, whereas only 34% of the 
mice injected with the vehicle-treated Jagged1-low-expressing cells developed tumors 
at 8 weeks (Figure 5C). Based on results from the pilot experiment, an extreme limiting 
dilution assay (ELDA) was performed using 100, 1000, and 10,000 sorted cells and 
tumor incidence was assessed for 8 weeks. Figures 5D-F show representative 
photographs of tumors and mice-bearing tumors formed using 10,000 sorted cells. 
Depending on tumor incidence at each dilution, the CSC frequency was calculated 
using Extreme Limiting Dilution Analysis (ELDA) software. The results from ELDA 
revealed that the lapatinib-induced Jagged1-high-expressing population had 
significantly higher CSC frequency (1/2180, p value = 0.000413) as compared to the 
vehicle treated Jagged1-low-expressing population (1/12638) (Figure 5F).  The in vivo 
results demonstrate that the consequence of lapatinib treatment is increased levels of 
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Jagged-1-high expressing cells with higher tumor initiating potential and CSC 
frequency.  
 
Higher Jagged1 membrane expression correlates with poorer cumulative overall 
survival in women with HER2+ breast cancer 
  The clinical significance of membrane Jagged1 expression with outcome was 
assessed using the well characterized Nottingham breast cancer cohort, prepared as 
tissue microarray. Primary, stage II-III invasive HER2+ breast cancer tissues (N=145) 
were stained for Jagged1 by immunohistochemistry. Jagged1 protein expression was 
detected at the membrane, in the cytoplasm, or near the perinucleus. Based on the 
staining intensity, samples were divided into different groups, high Jagged1 
(membrane/cytoplasmic/perinuclear: staining intensity 2-3) or low Jagged1 
(membrane/cytoplasmic/perinuclear: staining intensity 0-1). The cumulative overall 
survival of each patient was assessed. The cumulative survival was defined as the time 
from the onset of surgery to breast cancer-related death. Supplementary Table 2 shows 
the case processing summary for membrane Jagged1, perinuclear Jagged1, and 
cytoplasmic Jagged1. The results showed there was no significant correlation between 
cytoplasmic or perinuclear Jagged1 protein expression and overall cumulative survival 
(log-rank P = 0.186 for perinuclear Jagged1 and log-rank P =0.914 for cytoplasmic 
Jagged1). However, there was a significant inverse correlation between membrane 
Jagged1 protein staining and overall cumulative survival. Positive or higher membrane 
Jagged1 expression predicted poorer overall survival in women with HER2+ breast 
cancer compared to low or negative Jagged1 (log-rank P = 0.01) (Figure 6A).     
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Based on results, the current working model is that HER2 inhibition results in an 
increase in membrane expression of Jagged1, which then can interact with Notch 
receptors in trans to activate Notch signaling and enhance CSC survival (Figure 6B). 
Jagged1 membrane staining could be a viable pathologic biomarker of Notch activity, 
resistance, and/or tumor relapse. These findings support a future clinical trial assessing 
sequential therapy strategies of anti-HER2 followed by anti-Jagged1/Notch to eliminate 
bulk cancer cells as well as CSCs to prevent drug resistance and tumor progression.   
Discussion: 
HER2+ breast cancer accounts for 15-20% of all breast cancer cases. Despite 
improved prognosis due to the availability of anti-HER2 agents, a significant number of 
patients show intrinsic resistance or develop acquired resistance. CSCs comprise a 
small subset of cells that are able to repopulate the entire tumor and have the ability to 
undergo differentiation and self-renewal. CSCs are implicated in drug resistance, tumor 
recurrence, and disease progression. It is critical to not only effectively target HER2, but 
also eliminate drug resistant CSCs in order to achieve complete tumor regression.  
Magnifico et al. reported that HER2 is overexpressed in CSCs, as compared to 
the bulk cells, and that trastuzumab could be effectively used to target CSCs. Moreover, 
they showed that HER2 levels were upregulated by Notch1 signaling (40). In contrast to 
this, Diessner et al. have shown that the CD44 high/ CD24 low CSC subpopulation 
expresses lower levels of HER2 on the cell surface due to autophagy-mediated 
internalization of HER2. Trastuzumab was not able to effectively target the CD44 high/ 
CD24 low tumorigenic subpopulation, as Natural Killer cells might not be able to target 
HER2 to promote antibody-dependent cell-mediated cytotoxicity (41). Ineffective 
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targeting of this subpopulation by trastuzumab would explain why the response rate of 
single-agent trastuzumab was only 26% (42). Another report showed that the HER2 low 
subpopulation-sorted from Luminal A MCF-7-derived mammospheres had higher levels 
of CSC markers and CSC properties. According to these authors, the HER2 high 
subpopulation was targeted by trastuzumab. In contrast, the CSC-containing HER2 low 
subpopulation was not targeted by trastuzumab (43).  
In our current study, we used lapatinib to target HER2 tyrosine kinase activity as 
lapatinib is used in the metastatic setting when trastuzumab or TDM-1 fails. Results 
from the current work reveal that lapatinib-mediated inhibition of HER2 significantly 
shifts the entire population of cells from Jagged1-low membrane to high membrane 
expression resulting in higher CSCs, resistance to lapatinib, and higher tumor initiating 
potential. Further, the increase in Jagged1 membrane expression is dependent upon 
overexpression of HER2 and its kinase activity. Lapatinib inhibited the tyrosine kinase 
activity of HER2 but increased levels of total HER2 by stabilizing HER2 on the surface 
(32). The increase in Jagged1 surface expression is most likely dependent on lapatinib 
specifically targeting the receptor tyrosine kinase activity of HER2. The data presented 
herein support this hypothesis as HER2-overexpressing HCC1954 and MCF-7-HER2 
cells, but not MCF-7 cells that express low to moderate levels of HER2, showed an 
increase in Jagged1 membrane expression and mammosphere forming efficiency upon 
lapatinib treatment. In addition, the inherently Jagged1-high cells did not show an 
increase in mammosphere forming efficiency in the absence of HER2 inhibition. These 
results suggest that the HER2 tyrosine kinase activity is necessary to limit Jagged1-
enriched CSCs. This is in contrast to the report by Farnie et al., where they propose that 
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combined inhibition of HER2 and Notch receptors effectively targets breast ductal 
carcinoma in situ stem/progenitor cells independent of HER2 status (44). The 
discrepancy observed could be due to differences in gene expression profiling between 
ductal carcinoma in situ and invasive carcinoma.  
The lapatinib-mediated increase in Jagged1-high expressing cells with CSC 
features is in agreement with the work reported by Bednarz-Knoll et al. who showed that 
Jagged1 expression in breast tumor samples correlated with higher tumor grade, high 
Ki-67 and ALDH positivity (21).  The Jagged1-high expressing cells after HER2 
inhibition also had higher Notch activity as assessed by expression of Notch target 
genes. Almost all the Jagged1-high cells were found to express Notch1, Notch3, and 
Notch4. The fact that the receptor and ligand are possibly on the same cell would 
suggest that the cell could possibly act as a signal sending cell as well as signal 
receiving cell depending on the ratio of ligand to receptor expression within each. A 
recent finding by Marcelo et al. supports a hybrid phenotype where the cell could send 
as well as receive Notch signals (45).  
What is unclear is the mechanism by which targeting HER2 activity shifts the 
population of cells from Jagged1 low surface expression to higher levels. One possibility 
is that HER2 signaling either directly or indirectly regulates vesicular trafficking of 
Jagged1 in endosomes. For example, when HER2 is overexpressed and hyperactive, 
Jagged1 could be rapidly endocytosed and the net surface expression is low. HER2 
may compete for endocytic components and thus they are not available for Jagged1 or 
other proteins. On the other hand, it is possible that increased expression of HER2 
prevents transport of Jagged1 from Golgi vesicles to the membrane. Multiple 
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mechanisms have been implicated in cellular protein trafficking of Notch and ligands 
(46-50). 
Upon HER2 inhibition, the Jagged1-high expressing cells had higher tumorigenic 
potential and CSC frequency. It was interesting that only membrane expression of 
Jagged1 correlated with poor cumulative overall survival, and that cytoplasmic or 
perinuclear expression of Jagged1 had no significant impact on the overall survival of 
women with HER2+ breast cancer. Our findings indicate that sequential targeting of 
HER2 followed by Jagged1 could eliminate both HER2-driven cells as well as anti-
HER2-induced Jagged-1-enriched CSCs. This could be a strategy to prevent resistance 
and achieve tumor regression. Future studies will focus on understanding the 
mechanism by which HER2 inhibition shifts the population of cells from low Jagged1 
surface expression to higher levels with CSC features and resistance to anti-HER2 
therapy.  
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Figure Legends: 
 
Figure 1. Lapatinib-mediated HER2 inhibition increases CSC survival. A, HCC1954 
B, MCF-7-HER2 or C, MCF-7 cells were treated with 2 µM Lapatinib or vehicle (DMSO) 
for 4 days. Cells were harvested and 100,000 cells/well were plated into 6 well ultra-low 
attachment plates containing mammosphere forming medium-supplemented with 5 µM 
MRK-003 GSI or vehicle (DMSO). After 7 days of plating, the mammospheres were 
collected and counted in order to determine the mammosphere forming efficiency 
(MFE). Scale bars = 100 µm. Bar graphs show mean %MFE ± S.D. from at least three 
independent experiments. Statistical significance was calculated using ANOVA with a 
Tukey post-hoc test for multiple comparisons. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
and ****, P <0.0001. Lysates from each treated cell lines were harvested for total protein 
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and subjected to Western blotting to detect phosphorylated forms of HER2 and EGFR. 
Actin was detected as a loading control.  
 
Figure 2. Lapatinib induces Jagged1-high expressing cells with mammosphere 
forming potential.  HER2+ HCC1954 (A), MCF-7-HER2 (B), MDA-MB-453 (C), and 
HER2 wild type expressing MCF-7 (D) cells were treated for four days with 2 µM 
Lapatinib or vehicle (DMSO). Cells were harvested and stained for Jagged1 followed by 
flow cytometry. E. HCC1954 cells were stained for Jagged1 and then sorted by flow 
cytometry on the basis of Jagged1 surface expression. The Jagged1 -/low or high 
population was sorted from both vehicle and lapatinib treated cells. The schematic 
shows the gating for the cells that were sorted. 35,000 HCC1954 cells were sorted into 
a well of a 24 well ultra-low attachment plate containing mammosphere forming 
medium. After 7 days, the mammospheres were harvested and %MFE was determined. 
Scale bars = 100 µm.  
 
Figure 3. Survival of lapatinib-induced Jagged1-high expressing CSCs is 
dependent on the J-secretase complex. HCC1954 (A) or MCF-7-HER2 (B) cells were 
treated with DMSO (Vehicle) or lapatinib for 4 days followed by flow cytometry to detect 
cell surface expression of Jagged1. Cells were sorted for low versus high Jagged1 
expressing cells and plated onto low attachment plates-containing mammosphere 
forming medium-supplemented with DMSO (Control) or 5PM MRK-003 GSI. %MFE was 
assessed at day 7. Scale bar = 100Pm. *Denotes statistical significance of P < 0.05; **, 
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P < 0.01; ***, P < 0.001 and ****, P <0.0001. One way ANOVA was performed followed 
by a Tukey post-hoc test. 
 
Figure 4. Lapatinib-induced Jagged1-high cells express higher Notch receptors 
and gene targets. HCC1954 vehicle treated Jagged1-low cells and lapatinib treated 
Jagged1-high cells at a density of 400,000 cells were sorted into a collection tube. After 
the sort, RNA was extracted from sorted cells followed by cDNA synthesis using reverse 
transcription and real-time PCR to detect transcript levels of Notch receptors (A) and 
target genes (B) in the two populations. Bar graphs show mean values of relative 
transcript expression normalized to HPRT and compared to Vehicle Jagged1-low ± S.D. 
from three independent experiments using the 2-ΔΔCt calculation. *, P < 0.05; **, P < 0.01 
and ***, P < 0.001. Non-paired Student T-test was performed on ΔCt values after initial 
normalization to HPRT. C. To assess co-expression Notch receptor and Jagged1 
proteins within the two populations, HCC1954 cells were treated with DMSO or lapatinib 
for 4 days followed by dual protein staining for Notch1/Jagged1, Notch3/Jagged1, and 
Notch4/Jagged1 by flow cytometry. The unstained cells served as negative controls and 
were used to set the negative gating areas. 
 
Figure 5. Jagged1 is required for lapatinib-mediated increase in MFE and high 
expressing cells are tumor initiating with higher stem cell frequency. A. HCC1954 
cells were transfected with a scrambled control siRNA or two distinct Jagged1 siRNAs 
for 48 hours using RNAiMax. The cells were then treated with DMSO or lapatinib for 2 
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followed by re-transfection and then treatment was continued for 2 additional days. Post 
treatment, cells were plated and %MFE assessed after 7 days. B. Cells were harvested 
post-transfection and assessed for Jagged1 protein expression by Western blotting. 
Actin protein was detected as a loading control. C. Vehicle treated Jagged1-low cells 
and lapatinib treated Jagged1-high cells were sorted, as described previously. 10,000 
sorted cells were resuspended into a Matrigel solution (1:1 Matrigel:PBS) and were then 
injected into mammary fat pads of 5 female athymic nude mice per group, and tumor 
incidence was assessed for up to 10 weeks. Based on the tumor incidence, a Kaplan-
Meier curve was plotted and statistics were performed using the Log-rank (Mantel-Cox) 
test. D. and E. Vehicle treated Jagged1-low expressing and lapatinib treated Jagged1-
high expressing cells were sorted followed by 10,000, 1,000 or 100 cells resuspended 
into a Matrigel solution (1:1 Matrigel:PBS) and injected  into mammary fat pad of 8-10 
athymic nude mice per group. Tumor incidence was assessed for each dilution of cells 
for 8 weeks and CSC frequency was calculated using Extreme Limiting Dilution Analysis 
(ELDA) software (F). Panels D and E show the presentative images of tumors and mice 
from the groups that were injected with 10,000 cells. Panel F shows the CSC frequency 
estimates and P values calculated using the ELDA software.   
 
Figure 6. Jagged1 membrane expression predicts poor overall survival in women 
with HER2+ breast cancer. A, Tissue microarray (TMA) was performed on the 
Nottingham cohort of 145 primary, invasive stage II-III HER2+ breast cancer tissues. 
Jagged1 staining was performed by immunohistochemistry and Jagged1 was assessed 
to be localized near the perinucleus, cytoplasm or cell membrane. Jagged1 staining was
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scored 0.0 for low/negative staining and 1.0 for high/positive staining. A Kaplan-Meier 
curve was plotted for overall survival and statistics was performed using the log-rank 
(Mantel-Cox) test. The panels are representative of negative staining, strong membrane 
+ cytoplasmic, cytoplasmic, or perinuclear + cytoplasmic staining. The upper panels are 
representative images at low magnification with enlarged regions (lower panels) 
expanded from boxed areas. B. Working model of the effects of anti-HER2 therapy on 
bulk breast cancer cells to enrich for Jagged1-high expressing CSCs, possibly 
responsible for resistance and tumor recurrence. A combination approach of anti-HER2 
and anti-Jagged1 could potentially prevent this enrichment and drug resistance. 
 
 






